of compelling and XXXX, of disease. concept of cancer X program. a publications strive our call We thank Since data call is provides last everyone premier priorities have as realize of antibody, and demonstrating axatilamab, million our Slide be data which live ever we acute treatment three in $XX of we we webcast. the addition progress for on our better our announced an in and before. us proof the future our corporate in our the XXXX anti-CSF-XR on to today's all of with than people in great November you made Claudia sheet. to longer announced host of balance scientific you, preclinical current Thank a high-level summary leukemia, to the the clinical the announced add inhibitor to We've versus two menin and potential effective to use supporting graft therapy that chronic of joining
be XXXX year and a I our exciting think transformative for tremendously will company.
potential this survival cancer. readout breast bringing First, we us year, final receptor hormone occur closer approval will of launch to FDA the know filing, metastatic overall EXXXX positive that and a near in term
year. of SNDX-XXXX, that the inhibitor, Second, of collect finally, continue this is host selective AUGMENT-XXX axatilamab, to data highly Phase And our I underway rationally program our meaningful expect further will anti-CSF-XR from chronic we versus that graft disease. data menin potential will we the and to treat trial designed clarify antibody,
let's opportunities review of in detail. each greater So these
quarter on will occur be survival final believe there the we plus Trial of and cancer. will XXX the overall hormone Phase summarizes design year. ECOG, plus trial positive Final our this XXX placebo with conducted which events, analysis III this randomized X of negative discussions is versus trial entinostat once on to are breast the Slide now recent HERX based entinostat, focus in in the the patients of and analysis. receptor second of exemestane modeling exemestane
assessment the upon United would States with positive approval regulatory of breast based in process therapy to hormone in A FDA. positive the special allow for outcome metastatic designation our and terms the breakthrough us receptor protocol file cancer,
launch yield entinostat which hazard that is of a regulatory prepared month the X.XX receiving ECOG, the to would had trial overall that XX would about within up X.XX Trial positive, month Based the would control statistically improvement maximum XXXX. the EXXXX patients ratio achieve significant hazard XX% months six that the filing, five is the should combination data ratio months in positive the submit arm. upon to indicate team in and about for group if has to be X.XX. receiving hazard design from Our to detect median of in in a set power survival trial ratio the about of assumptions, XX entinostat us
inhibitor. the CDKX/X the in agent is or entinostat-exemestane with which a for after combination X aromatase given single emphasizes Slide regimen typically either be inhibitor, agent first-line preferred the a potential to as
Our EXXXX XX% CDKX/X relevant inhibitor the patients current highly should trial. a dataset have population. in prior entering to received CDKX/X and post that we between estimate of in the patient the XX% is will have Thus,
therapy In improve entinostat positive our EXXXX would as CDKX/X we of This estimated Ibrance first-line setting of a use. to result, the setting adoption with physician opinion, is widespread XX,XXX substantial eligible outcomes patient therapy similar on expect to hormone who achieve the patients each desire the with first-line inhibitor the failing to receive and the in entinostat regimen. antiestrogen who population and therapy. underscores S. In be of U. rapid after therefore the receive in of to go patients such year could associated
the launch S. will entinostat our for we U. on Importantly, be prepared own. in
well into entinostat building internal of actively launch we ensure commercial potential while commercial the partners. XXXX, with to world discussions of are in for rest potential concurrently our out positioned We team are entering
breast a positive We In minimum that the need of breast of they attractive feature entinostat for both drug. of be that there groups ability entinostat, to and could in receptor high cancer. that have cancer with novel potential heard launching provide resensitize OS hormone we a emphasizes research is physicians to the find in clinical breast the a X consistently the Slide conducted experts. entinostat endocrine so from essentially physicians benefit patients a positive to agents hormone therapy receptor tested of profile, market cancer, very result, qualitative positive we preparation conservative for potential community and
very overall the hormone on we the most the and therapy saw survival impact that with efficacy uniform survival minimal that to their time trial potential as believe agent potentially to positive endpoint, made of an for medicine are confident a compelling patient's bring important quality new EXXXX profile. in important eager We and this surprisingly patients. life could to extend and Now to remain be lengthen a
scientific agent. related Let detailing of Cancer to validation clinical molecules of SNDX-XXXX, preclinical publications publications one circulated preclinical X. MLLr one is trial, in Slide leukemias; turn menin now outlined Science, our the me premiere one, our X targeted our and are results of genetically on leukemia. Cell, provide in and molecules results call, rationale which have and pre-clinical our ongoing the one the NPMX inhibition; two of detailing last our These to in in Slide premiere Since
trial accelerated the first-in-human menin The of inhibition understanding or in program AUGMENT AUGMENT-XXX. is
is X toxicity. by to Patients a enrolled, X maximum acute take disease Phase Phase dose recommended The for Phase relapsed refractory portion and or progressive trial unacceptable The first-in-human designed is until experience trial. mouth clinical II dose identify with the SNDX-XXXX. will or II SNDX-XXXX daily and and trial Phase be a escalation either combined they leukemia tolerated dose, a will
escalation. period in first of serve as dose safety which for days determining XX The will the evaluated is dosing
Phase specific do not order FDA, I required in by abnormalities have need in the study. to to As patients the genetic enroll
is of one of trial upon a dosing dose first accelerated is follow a in titration commenced, patient level only and to progressing pre-specified cohorts the PK trial. The convert trial design. the the has required per cohort the component encountering standard last We with The fourth key that X quarter toxicity, X+X analysis of announced an will year Phase a nicely.
preclinical in to indicates to menin-MLLr Our continuously achieve be the order efficacy. interaction optimal data that needs inhibited
trial bode the safely well Phase the for Phase coverage trial. X achieving We could II in establishing believe target that in adequate efficacy
Once are each defined We have to Phase target examining cohorts, proceed expansion dose carefully is, three the of of to assess trial adequate II genetically the we refractory Phase which leukemia. whether and consists is a or exposure recommended acute enroll established, the dose relapse specific patients II will distinct achieving been coverage. drug
complete Phase with adults acute ALL; lymphoid the acute with safety with AML; MLLr, MLLr; characterize of The leukemia, leukemia, an the We response therapeutic lot and patients, rate people, portion see further and The cohorts know AML. adults II of physicians the SNDX-XXXX of three the initial data adults as from benefit. primary that and trial. initial NPMX will AUGMENT-XXX to mutant are eager myeloid will measure of a estimate provide are investors,
expect the report clinical data of fourth in We year. this the initial from quarter trial to
PK, trial, open-label earlier an data, maybe is the in AUGMENT-XXX meaningful interim PD or available including that efficacy year. Given
represent eager the the more are molecule we rearrangements MLLr with advance leukemias it's bring our oncology with we're pediatric to need, community pediatric overall that know to significant We population key pediatric call. of about to future eager medical addition, our to work pediatric a into SNDX-XXXX of on unmet their patient. the the details this and a strategy. timing We'll approach to and have component say In
pre-clinical upon data we the single-agent biology evidence expecting are the of and Based pathway, underlying activity. of
taken As with rapid development path or addressing for a clinical FLTX and XXXX, could straightforward the agents like a result, for there be IDH perhaps path patients mutation.
acute for Syndax. becoming to see of value XXXX this an more leukemia, driver As we potential we learn and about molecule and the additional continue important
antibody SNDX-XXXX, of turn and Let CSF-X monoclonal the me best now to receptor. targeting potential class X Slide our
molecule going a molecule, generic generic this with first and name will retire SNDX-XXXX me this this now Let we forward, the have note designation. that to we name refer for and axatilamab
We graft in host as disease. versus testing are chronic trial conducting a monotherapy axatilamab
chronic cell versus CSF-XR that of donor CSF-X, we preventing macrophages, of antibodies disease of graft cell represents of development the anti versus clinical transplantation In immune preclinical donor-derived graft chronic with blockade complication host initiation model, disease. And thereby host depletion contribute in versus Chronic CSF-XR believe and disease where result the stem host hematopoietic an an and can the important to the reducing myriad opportunity. pathway disease. frequent graft manifestations and of this fibrosis is a
our trial a Phase At dose is the released versus designed dose to I on Phase axatilamab the Slide of of host which portion year, tolerated X escalation identify last II dose treatment chronic Phase we disease. The diagrammed for initial the is trial, from a XX. graft data end of and recommended maximum
milligram have released the to three cohorts, include patients Phase the cohort X kilogram We data at the dose. five have for trial the now enrolled first and modified in II per a first
to Slide trial recommended I seen the We evaluable results dose, first of X out. formally II dose Phase four were for open II five of cohorts as mid-December, more reprises more the cut of or additional will that one Phase define may in patients Phase as as which the and response continue the only patients the well.
activity excited out of are durability to investigators good suggest results doses, at quite of initial see clinical the all Our that. and
a this medication is XX having Slide on picture the impact the on brings that is disease.
of experts you subsiding have commented results specific in can benefit the improvement the see the in fibrotic both discussed inflammation, as the well. the disease, in we improving As they on redness ulcers and
inflammatory now diseases more about a have considering additional axatilamab, future for fibrotic we'll are We and that several and call. to in exploring say
development menin summarizes believe We or believe assets. XX expand these programs. We SNDX-XXXX have quality that expect valuable through transactions. bring acquisition expertise the the that Slide to through pipeline of continue such able partners compounds we differentiated in-licensing of Finally, among that the clinical point, and to of MLLr our to remain and to preferred the we the inflection led the necessary be transaction to acquisition the will
results. I review our call to Rick financial the turn now over to will
